131 related articles for article (PubMed ID: 1866714)
21. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons.
Collen D; De Cock F; Stassen JM
Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918
[TBL] [Abstract][Full Text] [Related]
22. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
23. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
24. Platelet function after in vivo and in vitro treatment with thrombolytic agents.
Bertolino G; Noris P; Previtali M; Gamba G; Ferrario M; Montani N; Balduini CL
Am J Cardiol; 1992 Feb; 69(5):457-61. PubMed ID: 1736606
[TBL] [Abstract][Full Text] [Related]
25. Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
Eggers J; Ossadnik S; Hütten H; Seidel G
Thromb Haemost; 2009 Dec; 102(6):1274-7. PubMed ID: 19967161
[TBL] [Abstract][Full Text] [Related]
26. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
Onundarson PT; Francis CW; Marder VJ
J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
[TBL] [Abstract][Full Text] [Related]
27. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
[TBL] [Abstract][Full Text] [Related]
28. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
29. [Thrombolytic agents: efficacy in relation to evolution time and dose].
García Frade LJ; Torrado MC; Loren M; Navarro JL
Rev Clin Esp; 1989 Feb; 184(2):75-9. PubMed ID: 2502822
[TBL] [Abstract][Full Text] [Related]
30. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
31. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.
Torr-Brown SR; Sobel BE
Thromb Res; 1993 Dec; 72(5):413-21. PubMed ID: 8303684
[TBL] [Abstract][Full Text] [Related]
32. Platelet function and fibrinolytic agents: two sides of a coin?
Callahan KP; Malinin AI; Gurbel PA; Alexander JH; Granger CB; Serebruany VL
Cardiology; 2001; 95(2):55-60. PubMed ID: 11423707
[TBL] [Abstract][Full Text] [Related]
33. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
Andrew M; Brooker L; Leaker M; Paes B; Weitz J
Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
[TBL] [Abstract][Full Text] [Related]
34. Interactions between thrombolytic agents and platelets: effects of plasmin on platelet glycoproteins Ib and IIb/IIIa.
Hoffmann JJ; Janssen WC
Thromb Res; 1992 Sep; 67(6):711-9. PubMed ID: 1440536
[TBL] [Abstract][Full Text] [Related]
35. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
[TBL] [Abstract][Full Text] [Related]
36. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
37. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
38. Dissociation of clot retraction from platelet granule fusion and degranulation: an ultrastructural study of Reptilase-human platelet-rich plasma clots.
De Clerck F; Borgers M; de Gaetano G; Vermylen J
Br J Haematol; 1975 Feb; 29(2):341-8. PubMed ID: 1191554
[TBL] [Abstract][Full Text] [Related]
39. In vitro effects of rt-PA on platelet function and clot strength.
D'Amico EA; Chamone DA; Bydlowski SP
Thromb Res; 1997 Mar; 85(6):519-22. PubMed ID: 9101644
[No Abstract] [Full Text] [Related]
40. "Plasminogen steal" and clot lysis.
Torr SR; Nachowiak DA; Fujii S; Sobel BE
J Am Coll Cardiol; 1992 Apr; 19(5):1085-90. PubMed ID: 1532403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
